Written by: Eric Dallara, RPh
Download Here

The purpose is to provide guidance on side effect prevention and management to minimize treatment interruptions. Diarrhea is a common side effect of Neratinib treatment occurring in 95% of patients in the ExteNET trial on the Neratinib arm.1 The majority 93% of the patients experienced diarrhea in the first month of treatment so there is a great need for prevention and close patient monitoring during the first months of therapy.
Continue reading Neratinib Diarrhea Management

Read More

Written by: Derek Gyori, PharmD and Julianne Orr, PharmD
Download Here

Abemaciclib is an FDA approved Cyclin Dependent Kinase (CDK) 4 and 6 Inhibitor approved for use in hormone receptor (HR) positive and human epidermal growth factor 2 (HER2) negative metastatic breast cancer. Abemaciclib works downstream of the estrogen receptor to halt the progression from the G1 phase to S phase that is a critical step in the replication of cancerous cells.1-3 Abemaciclib has been studied across multiple lines of therapy for metastatic breast cancer and is FDA-approved in combination with an aromatase inhibitor, fulvestrant, and as a single agent. In addition, these studies have shown a lower risk of neutropenia but an increased risk of diarrhea compared to other approved CDK 4&6 inhibitors.1,2,3 Continue reading Management of Abemaciclib Associated Diarrhea

Read More

Written By: Todd Murphree, PharmD
Download Here

Description Venetoclax (Brand name: VENCLEXTA) is an oral BCL-2 inhibitor that is indicated for the treatment of CLL in patients with 17p deletion who have received at least one prior line of therapy. Venetoclax has a specific dose titration schedule and recommendations for patients in different risk categories for Tumor Lysis Syndrome (TLS). This poses potential challenges in the workflow of dispensing the drug. Continue reading Venetoclax Dispensing Procedure

Read More

Written by: Danny Olszta, PharmD, BCOP Jolliet Oncology Hematology Associates
Download Here

For patients with Non‐Small Cell Lung Cancer (NSCLC) that have a del 19 EGFR mutation appropriate for first‐line treatment with an epidermal growth factor receptor (EGFR) Inhibitor, Afatinib (Gilotrif) has a clear overall survival (OS) benefit compared to chemotherapy. If another EGFR inhibitor is being prescribed for a patient with a del 19 EGFR mutation, the pharmacist will contact the Physician to determine why the current therapy was chosen.

Continue reading EGFR Inhibitors

Read More